Physician
Dobbs, Vilma
Dobbs, Vilma was paid $995K by Medicaid between Jan 2020 and Nov 2021, across 42 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 34% of everything it billed.
33Billing provider infoDOBBS, VILMA
SILVER SPRING, MD 20910
SILVER SPRING, MD 20910
33aNPI1417144221assigned 09/26/2007
33bProvider typePediatrics Physician
28Total paid$995K
24GClaims30,796
24DCodes billed42
24AFirst – last monthJan 2020 – Nov 2021
Compared with peers
Next to other Pediatrics Physician providers in Maryland
Rank by total paid#85 of 306
Median peer was paid$206K
This provider vs. median4.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 19,218 | $599K | |
| 2021 | 11,578 | $397K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 34% | 4,681 | 4,211 | $342K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 15% | 1,337 | 1,307 | $154K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 15% | 1,409 | 1,388 | $149K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 8.7% | 828 | 815 | $86K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 3.6% | 371 | 353 | $36K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.3% | 758 | 721 | $33K |
| 92551 | 2.7% | 2,825 | 2,767 | $27K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.8% | 156 | 153 | $18K |
| 90686 | 1.6% | 684 | 681 | $16K | |
| 90651 | 1.4% | 595 | 586 | $14K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.2% | 1,436 | 1,398 | $12K |
| 90620 | 1.2% | 546 | 522 | $12K |
30 more codes
| 36415 | Collection of venous blood by venipuncture | 1.2% | 4,536 | $12K |
| 90734 | 1.1% | 465 | $11K | |
| 96127 | <1% | 1,873 | $9K | |
| 90670 | <1% | 368 | $8K | |
| 90698 | <1% | 365 | $8K | |
| 99177 | <1% | 1,828 | $7K | |
| 92587 | <1% | 344 | $6K | |
| 90680 | <1% | 221 | $5K | |
| 90715 | <1% | 209 | $5K | |
| 90633 | <1% | 194 | $4K | |
| 90710 | <1% | 176 | $4K | |
| 99173 | <1% | 1,524 | $4K | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | <1% | 587 | $3K |
| 90696 | <1% | 92 | $2K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 243 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 86 | $2K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 13 | $1K |
| 81003 | <1% | 597 | $1K | |
| 96160 | <1% | 1,004 | $1K | |
| 90744 | <1% | 42 | $956.32 | |
| 90707 | <1% | 30 | $651.84 | |
| 99051 | <1% | 84 | $440.00 | |
| 90716 | <1% | 16 | $372.48 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 87 | $367.92 |
| 3011F | <1% | 57 | $300.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 15 | $222.75 |
| 96161 | <1% | 69 | $79.95 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 15 | $9.90 |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 15 | $7.80 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 15 | $0.60 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.